On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

AstraZeneca (South Korea)

InstitutionResearch output, impact & collaborations

AstraZeneca (South Korea) is a institution indexed in ScholarIQ from OpenAlex.

What is known about AstraZeneca (South Korea)?

ScholarIQrecord summary

AstraZeneca (South Korea) is a research organisation in Seoul, KR. OpenAlex records 1,052 works and 54,221 citations for it. 560 researchers list it as their most recent affiliation.

How many works does AstraZeneca (South Korea) have?

ScholarIQindexed works

AstraZeneca (South Korea) has 1,052 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for AstraZeneca (South Korea) →

How many citations does AstraZeneca (South Korea) have?

ScholarIQcitation count

AstraZeneca (South Korea) has 54,221 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for AstraZeneca (South Korea) →

How many researchers are at AstraZeneca (South Korea)?

ScholarIQresearcher count

AstraZeneca (South Korea) has 560 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at AstraZeneca (South Korea)?

ScholarIQavg h-index

AstraZeneca (South Korea) has an average h-index of 47.5 in OpenAlex.

Open the OpenAlex record →

What is the ROR of AstraZeneca (South Korea)?

ScholarIQror

The ROR for AstraZeneca (South Korea) is on the source record.

Open the ROR →

What is the OpenAlex record for AstraZeneca (South Korea)?

ScholarIQopenalex

The OpenAlex for AstraZeneca (South Korea) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind AstraZeneca (South Korea)?

ScholarIQtop researchers by citations

Zhongwu Lai · Lung Cancer Research Studies

304 works32,995 citations

Peter B. Cotton · Gallbladder and Bile Duct Disorders

490 works25,635 citations

Kenneth S. Thress · Lung Cancer Treatments and Mutations

108 works7,973 citations

David W. Boulton · Diabetes Treatment and Management

197 works7,268 citations

What are the most-cited papers on AstraZeneca (South Korea)?

ScholarIQmost cited works

A lexicon for endoscopic adverse events: report of an ASGE workshop

Peter B. Cotton, Glenn M. Eisen, Lars Aabakken, Todd H. Baron, Matt M. Hutter, Brian C. Jacobson, Klaus Mergener, Albert A. Nemcek, Bret T. Petersen, John L. Petrini, Irving M. Pike, Linda Rabeneck, Joseph Romagnuolo, John J. Vargo

Gastrointestinal Endoscopy. 20102,462 Citations

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard

Nature Medicine. 20151,558 CitationsOPEN ACCESS

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden, Rachael Lawrance, Cloud P. Paweletz, Mireille Cantarini, James Chih‐Hsin Yang, J. Carl Barrett, Pasi A. Jänne

Journal of Clinical Oncology. 2016846 CitationsOPEN ACCESS

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Peter Ballard, James Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren A.E. Cross

Clinical Cancer Research. 2016725 Citations

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne

JAMA Oncology. 2018691 CitationsOPEN ACCESS

How much of the research on AstraZeneca (South Korea) is open access?

ScholarIQopen access share

67%OPEN ACCESS

Gold

Green

17%

Hybrid

Bronze

33%

Closed

33%